Online citations, reference lists, and bibliographies.
← Back to Search

Randomized, Controlled Phase II Trial Of Subcutaneous Interleukin‐2 In Combination With Highly Active Antiretroviral Therapy (HAART) In HIV Patients

U. Hengge, M. Goos, S. Esser, V. Exner, H. Dötterer, H. Wiehler, C. Borchard, K. Müller, A. Beckmann, M. T. Eppner, A. Berger, M. Fiedler
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Objective:To determine the immunological, virological and clinical effects of subcutaneous IL-2 in 44 HIV-patients in conjunction with pre-existing tri-therapy (zidovudine, 3TC, saquinavir). Design:Partially randomized, controlled, prospective trial. Setting:Single center study at tertiary care center. Patients:Sixty four patients (CD4 count 200–500 × 106/l). Intervention:Fourty four patients were randomized to receive 5-day cycles of IL-2 (9 Mio IU/d) every 6 weeks (Group A) or whenever the CD4 cell count dropped below the 1.25-fold of baseline (Group B), whereas 20 control patients received the same HAART without IL-2. Outcome measures:The optimal individual treatment interval and the immunological and virological effects of subcutaneously administered IL-2 were analysed. Importantly, the level of cellular in vivo immunity and the frequency of dermatological marker diseases and infectious complications were assessed. Results:IL-2 was well tolerated although fever, influenza-like symptoms and indurated injection sites were commonly encountered. After 1 year of IL-2, there was a median increase of more than 100 × 106/l CD4 cells in both IL-2 groups in contrast to the controls (P < 0.01, 0.01 and not significant). The median HIV load did not increase either in plasma or in lymph nodes. Lymphocyte activation decreased as assessed by MHC class II (P < 0.001), CD25 (P < 0.001) and CD38 expression (P < 0.005). Although delayed type hypersensitivity against common recall antigens increased in both IL-2 groups, it did not reach statistical significance. However, it is of note, that in 7 of 11 (63.6%) patients delayed type hypersensitivity against recombinant HIV antigens improved significantly. Whereas there was no opportunistic infection in either IL-2 group, three cases of Kaposi's sarcoma occurred in the controls. Dermatological indicator diseases (thrush, condyloma, herpes simplex) were found to occur more frequently in the control group. Conclusions:Subcutaneous IL-2 in addition to HAART was safe and led to sustained qualitative and quantitative immunological improvements in the majority of patients. Individualisation of therapy intervals further improved the efficacy and tolerance of IL-2.
This paper references
10.1016/S0140-6736(75)91813-9
MONGOLISM BY TERTIARY TRISOMY
R. Chaganti (1975)
10.1172/JCI110981
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.
A. Rook (1983)
10.1016/S0140-6736(84)92220-7
HUMAN RECOMBINANT INTERLEUKIN-2 PARTLY RECONSTITUTES DEFICIENT IN-VITRO IMMUNE RESPONSES OF LYMPHOCYTES FROM PATIENTS WITH AIDS
J. Lifson (1984)
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
J. Gerdes (1984)
10.1001/JAMA.1987.03400120074028
Dermatologic changes associated with interleukin 2 administration.
A. Gaspari (1987)
10.1126/SCIENCE.3131876
Interleukin-2: inception, impact, and implications.
K. Smith (1988)
10.1097/00126334-199101000-00002
Safety and Effects of Interleukin‐2 Plus Zidovudine in Asymptomatic Individuals Infected with Human Immunodeficiency Virus
D. Schwartz (1991)
10.1097/00005650-199108000-00011
A Health Status Questionnaire Using 30 Items From The Medical Outcomes Study: Preliminary Validation in Persons With Early HIV Infection
A. Wu (1991)
10.1200/JCO.1991.9.4.694
Interleukin-2 toxicity.
J. Siegel (1991)
Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.
A. G. Clark (1992)
10.1006/CLIN.1993.1063
The impaired in vitro production of interleukin-2 in HIV infection is negatively correlated to the number of circulating CD4+DR+ T cells and is reversed by allowing T cells to rest in culture: arguments for in vivo CD4+ T cell activation.
O. Lees (1993)
10.1172/JCI116161
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
M. Caligiuri (1993)
10.1097/00002030-199401000-00009
A Phase I study of subcutaneous recombinant interleukin‐2 in patients with advanced HIV disease while on zidovudine
D. McMahon (1994)
10.1006/CLIN.1994.1052
The interleukin-2 receptor subunit expression and function on peripheral blood lymphocytes from HIV-infected and control persons.
G. Vanham (1994)
HIV load in lymphoid tissues using branched DNA (bDNA) signal amplification
P Dailey (1994)
10.1097/00042560-199504120-00003
Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.
C. Pachl (1995)
10.1038/NG0695-161
Cytokine gene expression in epidermis with biological effects following injection of naked DNA
U. Hengge (1995)
10.1084/JEM.182.3.789
Defective natural immunity: an early manifestation of human immunodeficiency virus infection
H. Ullum (1995)
10.1056/NEJM199503023320904
Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.
J. Kovacs (1995)
10.1007/BF02918280
Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement
A. Kinter (1996)
10.1016/S0140-6736(05)65920-X
HIV-Related Skin Diseases
A. Geusau (1996)
10.1016/0167-5699(96)10057-C
Interleukin 2 and its receptors: recent advances and new immunological functions.
J. Théze (1996)
10.3109/00365549609049062
An eleven year follow-up of delayed-type hypersensitivity testing for the identification of HIV-1 infected patients at increased risk of developing AIDS.
A. Karlsson (1996)
10.1056/NEJM199610313351803
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
J. Kovacs (1996)
10.1073/PNAS.93.19.10405
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.
E. L. Jacobson (1996)
IL2 relieves spontaneous G1 arrest in CD8+ T-cells from HIV+ individuals
RA Lempicki (1996)
10.1056/NEJM199709113371102
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
R. Gulick (1997)
10.1086/517328
Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States.
M. Harris (1997)
10.1038/NM0597-533
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
M. Connors (1997)
10.1111/j.1365-2133.1997.tb03793.x
The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression
S. Uthayakumar (1997)
10.1086/513971
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.
R. Davey (1997)
10.1006/CLIN.1996.4298
Human immunodeficiency virus (HIV) type-1 GP120-specific cell-mediated cytotoxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects: enhancement with interleukin-2(IL-2), IL-12, and IL-15.
S. J. Lin (1997)
Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
B. Zerhouni (1997)
HIV infection induces changes in CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
M Connors (1997)
10.1093/JAC/42.2.269
Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.
H. Vahaboğlu (1998)
10.1128/AAC.42.2.269
A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs
K. Hertogs (1998)
10.1097/00002030-199808000-00010
No evidence for proliferation in the blood CD4+ T‐cell pool during HIV‐1 infection and triple combination therapy
Olivier Tissot (1998)
10.1038/nm0298-215
Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
G. Gorochov (1998)
10.1001/JAMA.1997.03540480062040
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
C. Carpenter (1998)



This paper is referenced by
10.1002/14651858.CD009818.pub2
Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults
Jennifer Onwumeh (2017)
10.1111/imr.12083
Immune interventions in HIV infection
G. Carcelain (2013)
NanoAPC deliver antigen, IL-2 and co-stimulatory molecules to antigen specific T cells and activate viral specific T cells in chronic infections
M. Liu (2011)
Immune reconstitution in HIV-1 infection : the effects of antiretroviral and immune therapy
A. Sullivan (2011)
10.1371/journal.pone.0009334
Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study
J. Tavel (2010)
10.1007/s10875-010-9432-3
IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the Periphery
L. Ndhlovu (2010)
Title IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD 4 + T ( TH 17 ) Cells in the Periphery Permalink
L. Ndhlovu (2010)
10.1002/ajh.21422
A 57‐year‐old HIV‐positive man with persistent fever, weight loss, and pancytopenia
V. Zota (2009)
10.1586/17476348.3.1.53
Cytokine therapy of tuberculosis at the crossroads
R. Reljic (2009)
10.2217/14796708.3.5.565
Preventing brain damage in HIV infection
Å. Mellgren (2008)
10.1089/AID.2007.0209
Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy.
U. Sriram (2007)
10.1097/QAD.0b013e3282703825
Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048–079 Trials)*
C. Durier (2007)
10.1186/1476-8518-5-6
A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy
G. Hardy (2007)
10.1016/J.JACI.2006.12.674
Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402.
S. Pahwa (2007)
10.1371/journal.pmed.0030011
An Alternative and Effective HIV Vaccination Approach Based on Inhibition of Antigen Presentation Attenuators in Dendritic Cells
Xiaotong Song (2006)
10.1007/s11481-006-9060-0
Neuroprotective and Antiretroviral Effects of the Immunophilin ligand GPI 1046
J. Steiner (2006)
10.1016/S0140-6736(06)67941-5
Interleukin-2 therapy and CD4+ T cells in HIV-1 infection
S. Vento (2006)
10.1093/JAC/DKH557
Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
G. Marchetti (2005)
Immune reconstitution in HIV-infected children on antiretroviral therapy
S. Gracía (2005)
10.4049/jimmunol.174.4.1913
Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251
J. Nacsa (2005)
10.1097/01.qai.0000182848.45722.b7
Quality of Life in a Clinical Trial of Highly Active Antiretroviral Therapy Alone or With Intravenous or Subcutaneous Interleukin-2 Administration
B. Martin (2005)
10.1080/00365540510012099
Advanced acute myelogenous leukaemia (AML) during HAART-treated HIV disease, manifesting initially as a thyroid mass
R. Manfredi (2005)
10.1097/00002030-200501030-00005
Circulating proviral HIV DNA and HIV-associated dementia
B. Shiramizu (2005)
SIVmac 251 in Macaques Chronically Infected with T Cells + and CD 8 + Virus ( SIV )-Specific CD 4 Vaccine-Boosted Simian Immunodeficiency Contrasting Effects of Low-Dose IL-2 on
J. Nacsa (2005)
10.1517/13543776.15.9.1115
Immunomodulants in HIV infection
A. Bandera (2005)
10.1097/00002030-200410210-00003
Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART
B. Martinez-Mariño (2004)
10.1073/PNAS.0308381100
An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.
J. Saavedra-Lozano (2004)
10.1097/00002030-200410210-00004
T-cell function after interleukin-2 therapy in HIV-infected patients is correlated with serum cortisol concentrations
M. Lindemann (2004)
10.1007/978-3-0348-7869-2_2
A perspective of the history of HAART
D. Konopnicki (2004)
10.1097/00002030-200411050-00014
Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses
G. Hardy (2004)
10.1023/B:JOCI.0000019778.96564.26
Effect of IL-2 Therapy on CD8+ Cell Noncytotoxic Anti-HIV Response During Primary HIV-1 Infection
B. Martinez-Mariño (2004)
10.1310/MB7D-MKTM-QPG5-HHUD
Nitric Oxide Production in HIV-1 Infected Patients Receiving Intermittent Cycles of Interleukin-2 and Antiretrovirals
D. Torre (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar